Recurrent herpes simplex virus (HSV) infection of the skin or mucous membranes of humans has been a considerable source of discomfort and disability. The treatments clinically available at this time for this infection, both topically and/or systemically, have been less than satisfactory.
Recent reports have described an excellent, reproducible experimental laboratory animal infection model involving inoculation of the skin of hairless mice with HSV (1, 5, 6, 11) . After HSV inoculation of scarified, lumbosacral hairless-mouse skin, the animals developed a punctate eruption within 3 to 4 days, which rapidly coalesced to form a band-like lesion in 5 to 6 days with neurodermatomic distribution resembling the skin lesions of herpes zoster infection rather than human cutaneous HSV infection. There is evidence that in this skin infection model the virus spreads eventually to the central nervous system (CNS) and causes encephalitis with paralysis and ultimately death (1) .
This model provides an experimental system in which a variety of topically or systemically administered antiviral agents may be evaluated in vivo. Underwood (11) and Lieberman et al. In the present study, the experimental model of HSV infection of hairless mice was used to evaluate the antiviral activity of several compounds to determine their potential usefulness in herpetic infections. 6-Azauridine (aza-U), 5-iodo-2'-deoxyuridine (IUdR), and ara-A have already been shown to have an inhibitory effect upon HSV multiplication in vitro (2, 3, 8) , and therapeutic activity in experimental animals and humans has also been demonstrated (4, 7, 9) .
MATERIALS AND METHODS Virus. The S type-1 HSV strain, originally isolated from a human facial skin lesion and passaged in HEp-2 cell cultures, was obtained from Paul E. Came, Schering Corp., Bloomfield, N.J. The strain was propagated in our laboratory in secondary rabbit kidney cell cultures and had a titer of 4 x 106 plaque-forming units per ml when assayed on Vero cell monolayers. Samples of the same batch of virus were stored at -70 C until used throughout the experiments. For the infection of mice, a virus dilution containing 40 skin meAn infective dose per ml was used.
Mice. Hairless mice, randomly bred at the New York University School of Medicine animal laboratory facility, were originally derived from the HRS/Y strain of Jackson Laboratories, Bar Harbor, Me. Mice weighing 20 2 g were segregated in groups of 10, according to sex and birth date.
Infection of mice. The procedures used were as described (5) 
RESULTS
Evolution of the infection. After cutaneous inoculation with HSV, the evolution of the skin lesions was essentially similar to the pattern described by Lieberman et al. (5) . A few animals which did develop cutaneous infection, but which had no CNS involvement, showed complete healing of the skin lesions within 3 to 4 weeks. In very rare instances, mice which developed CNS disease did survive, but with some residual paralysis.
Effect of ara-A. When ara-A was given i.p. in daily doses of 300 mg/kg for 12 days starting at the time of infection, 90 to 100% of the mice survived, and the average lesion score was reduced by 25% (Table 1) . Correspondingly, a more rapid healing of the lesions was also apparent ( Table 2) . The same dose, starting at the time of inoculation, given every 2nd day over a 12-day period seemed to be ineffective, as evidenced by the high average lesion score and no difference in the rate of survival and the (Table 1) . Starting the treatment 1 or 2 days after the infection had approximately the same protective effect on the survival of the mice as had treatment started at the time of infection (Table 1) ; however, a significant decrease in the severity of the lesions and a marked reduction of healing time was seen in the former group of animals (Tables 1  and 2 ). The best results were obtained when a daily dose of 600 mg/kg was given over a period of 6 days and by starting the treatment 24 h after infection (Table 1) .
Effect of IUdR. IUdR in doses of 100 mg/kg and given daily from the time of inoculation for 12 days significantly reduced the severity of the HSV-induced lesions and increased mouse survival (Table 3 When infected animals were given ara-A i.p. from day 0 to day 11 after inoculation in doses of 300 mg/kg (total dose 3,600 mg), a marked reduction in skin lesion severity was seen, and protection from fatal spread to the CNS was shown that when a total amount of 3,000 mg/kg was given within the first 2 days after infection, no therapeutic effect was obtained (10) . In our experiments, the best results were obtained with a total dose of 3,600 mg administered over a period of 6 successive days. The use of the HSV-hairless mouse model for the evaluation of IUdR as an antiviral agent showed that a total dose of 1,000 mg of IUdR reduced the severity of skin lesions and the incidence of paralysis and death, and also increased the mean survival time of infected animals. The same favorable effect seen with ara-A when the initiation treatment was delayed for 2 days after inoculation was also observed with IUdR. Mice treated on the 3rd day after the herpetic lesions had developed did not benefit from IUdR treatment.
Lack of protection and enhancement of the severity of HSV infection by aza-U treatment was manifested by a decrease in the mean survival time in the aza-U-treated mice as compared with that of the HSV-infected untreated controls. The potentiation of HSV infection by aza-U may be related to the observation (5) that USV-infected mice treated with ara-C similarly exhibited a 100% mortality as compared with the 60% death rate in the infected, untreated control group (P < 0.05). We attribute these effects to the toxicity of these compounds, which may influence the course of infection by diminishing the natural resistance of the treated mice. Drug toxicity also might explain the few deaths observed after ara-A and IUdR treatments in HSV-infected mice, deaths not necessarily attributable only to the antiviral activity failure of these compounds.
The better antiviral effect achieved when treatment with either ara-A or IUdR was delayed for 24 or 48 h after infection could have been caused by the toxicity of these compounds, by the stress produced by the physical handling of the animals, or by the injection itself, which could have promoted the spread of the infection.
